PURA

Chr 5AD

purine rich element binding protein A

Also known as: MRD31, NEDRIHF, PUR-ALPHA, PUR1, PURALPHA

This gene product is a sequence-specific, single-stranded DNA-binding protein. It binds preferentially to the single strand of the purine-rich element termed PUR, which is present at origins of replication and in gene flanking regions in a variety of eukaryotes from yeasts through humans. Thus, it is implicated in the control of both DNA replication and transcription. Deletion of this gene has been associated with myelodysplastic syndrome and acute myelogenous leukemia. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
LOFmechanismADLOEUF 0.341 OMIM phenotype
Clinical SummaryPURA
🧬
Gene-Disease Validity (ClinGen)
complex neurodevelopmental disorder · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.94). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
221 unique Pathogenic / Likely Pathogenic· 190 VUS of 630 total submissions
📖
GeneReview available — PURA
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.34LOEUF
pLI 0.940
Z-score 2.77
OE 0.00 (0.000.34)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?
3.37Z-score
OE missense 0.25 (0.190.32)
39 obs / 158.3 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?
LoF OE?0.00 (0.000.34)
00.351.4
Missense OE?0.25 (0.190.32)
00.61.4
Synonymous OE?1.53
01.21.6
LoF obs/exp: 0 / 8.9Missense obs/exp: 39 / 158.3Syn Z: -3.51
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitivePURA-related intellectual disabilityLOFAD

This gene — mechanism propensity

DN
0.3296th %ile
GOF
0.3887th %ile
LOF
0.83top 5%

The highest-scoring mechanism for this gene is loss-of-function (haploinsufficiency).

LOFprediction above median · 1 literature citation · 67% of P/LP variants are LoF · LOEUF 0.34 · ClinGen HI: Sufficient evidence for dosage pathogenicity

Literature Evidence

LOFRecently, haploinsufficiency of PURA has been identified as an essential cause of 5q31.3 microdeletion syndrome, which is characterized by severe psychomotor developmental delay, epilepsy, distinctive features, and delayed myelination.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 29619234

ClinVar Variant Classifications

630 submitted variants in ClinVar

Classification Summary

Pathogenic131
Likely Pathogenic90
VUS190
Likely Benign180
Benign20
Conflicting18
131
Pathogenic
90
Likely Pathogenic
190
VUS
180
Likely Benign
20
Benign
18
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
107
22
2
0
131
Likely Pathogenic
42
48
0
0
90
VUS
2
147
7
34
190
Likely Benign
0
43
1
136
180
Benign
0
10
1
9
20
Conflicting
18
Total15127011179629

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

13 pathogenic / likely-pathogenic (of 19) ClinVar copy-number / structural variants overlap PURA — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

PURA · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →